PharmTech

Overcoming Formulation Challenges for Biosimilars

Biosimilar formulation development requires navigating around scientific, regulatory, and legal challenges, according to Sung ...
FiercePharma

Antiviral Drug Development: How NanoViricides is Overcoming Challenges to the Current Model

As viruses evolve to resist vaccines and therapeutics, new targeted approaches to deliver broad-spectrum antivirals are needed. In this podcast, Anil Diwan, President and Executive Chairman of ...

WuXi AppTec’s CRDMO Model: Linking Research, Development, and Manufacturing Across the Drug Development Lifecycle

SHANGHAI, SHANGHAI, CHINA, April 30, 2026 /EINPresswire.com/ -- In today’s life sciences industry, moving a drug ...
Harvard Business ReviewOpinion

U.S. Medical Centers Need a New Model for Drug Discovery and Development

U.S. academic medical centers risk losing leadership in drug discovery and development as global competition—especially from ...
The Scientist

Drug Discovery: From Target Identification to Clinical Candidate

Barbara Slusher explains the hit-to-lead optimization process, high-throughput screening, and the role of AI and organoids in ...
ascopubs.org

Oncology Drug Development: Challenges of Increasingly Available Therapies

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) The following represents ...
Forbes

Global Drug Development Shifts East

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

WuXi AppTec Supports a More Connected Life Sciences Ecosystem Through Collaboration

SHANGHAI, SHANGHAI, CHINA, April 30, 2026 /EINPresswire.com/ -- The development of new medicines increasingly depends ...
Becker's Hospital Review

Exclusion lists pose a challenge to drug developers

With drug prices on the rise, more and more drugs will be deemed ineligible for reimbursement, challenging drug developers to provide evidence of clinical superiority. Exclusion lists, which catalogue ...